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Abstract
Background: Despite clinical descriptions of severe vivax malaria cases having been reported, data regarding
immunological and inflammatory patterns are scarce. In this report, the inflammatory and immunological status of
both mild and severe vivax malaria cases are compared in order to explore immunopathological events in this
disease.
Methods and Results: Active and passive malaria case detections were performed during 2007 in Buritis,
Rondônia, in the Brazilian Amazon. A total of 219 participants enrolled the study. Study individuals were classified
according to the presence of Plasmodium vivax infection within four groups: non-infected (n = 90), asymptomatic
(n = 60), mild (n = 50) and severe vivax infection (n = 19). A diagnosis of malaria was made by microscopy and
molecular assays. Since at present no clear criteria define severe vivax malaria, this study adapted the consensual
criteria from falciparum malaria. Patients with severe P. vivax infection were younger, had lived for shorter time in
the endemic area, and recalled having experienced less previous malaria episodes than individuals with no malaria
infection and with mild or asymptomatic infection. Strong linear trends were identified regarding increasing
plasma levels of C reactive protein (CRP), serum creatinine, bilirubins and the graduation of disease severity. Plasma
levels of tumour necrosis factor (TNF), interferon-gamma(IFN-gamma) and also IFN-gamma/interleukin-10 ratios
were increased and exhibited a linear trend with gradual augmentation of disease severity. Both laboratory
parameters of organ dysfunction and inflammatory cytokines were reduced during anti-parasite therapy in those
patients with severe disease.
Conclusion: Different clinical presentations of vivax malaria infection present strong association with activation of
pro-inflammatory responses and cytokine imbalance. These findings are of utmost importance to improve current
knowledge about physiopathological concepts of this serious widespread disease.
Background
Plasmodium vivax infection has been considered for a
long time a benign and self-limited disease, mainly
when compared to the burden of Plasmodium falci-
parum infection in African countries [1]. Nevertheless,
P. vivax is responsible for up to 400 million infections
each year, representing the most widespread Plasmo-
dium species [2]. Plasmodium vivax accounts for the
majority of malaria cases within the Brazilian Amazon
[3], and the prevalence of asymptomatic infection is very
high [4,5]. Historically, cases of complicated P. vivax
malaria have been rare, and documented almost
exclusively by case reports or small case series [6-8].
Recent evidence from larger studies performed in Mela-
nesian populations has however reinforced the associa-
tion between vivax malaria, severe complications, and
death [9-11]. Severe complications associated with vivax
malaria have also been reported in the Amazon region
[12]. Together with rising documentation of drug resis-
tance worldwide, the complications of P. vivax infection
represent a global health menace which needs focused
efforts to its resolution.
Major severe P. vivax clinical syndromes documented
include important thrombocytopaenia [13,14], cerebral
malaria [15,16], and acute renal [7,17], hepatic [6] and
pulmonary [18,19] dysfunctions. In severe falciparum
malaria syndromes, as in many other systemic
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a consequence of an intense inflammatory burst,
favoured by a pathological activation of the immune sys-
tem and cytokine release [20-22]. Despite clinical
descriptions of the illness caused by P. vivax infection,
data regarding immunological and inflammatory pat-
terns are scarce. In the present report, inflammatory
and immunological status of both mild and severe vivax
malaria cases were compared in order to explore immu-
nopathological events in this disease.
Methods
Study localities
A study investigating determinant factors for vivax
malaria severity was performed during 2007 in Buritis
(10°12’43” S; 63°49’44” W), a recent urbanized munici-
pality of the Rondônia State, in the south-western part
of Brazilian Amazon. Within this region, malaria trans-
mission is unstable, with increased number of cases
being detected annually between April to September,
and the risk of infection is high [23], with an Annual
Parasite Incidence of 77.5 per 1,000 inhabitants in 2005
[3]. The prevalence of P. falciparum infection in the
Brazilian Amazon is 23.7% [3], and Plasmodium malar-
iae case detection reaches 10% in Rondônia [24].
Participants and sampling
Active and passive malaria case detections were per-
formed. These included home visits in areas of high dis-
ease transmission, and study of individuals who seek care
at the diagnostic centers of Brazilian National Foundation
of Health (FUNASA), responsible for malaria control in
the country. In addition, patients admitted to the Buritis
municipal Hospital (Hospital São Gabriel) presenting
clinical signs of mild or complicated malaria were also
included in the study. All individuals from fifteen to
seventy years, of both sexes, who had been residing in the
endemic area for more than six months, were invited to
be included in the study. Exclusion criteria were: docu-
mented or strong clinical suspecting of viral hepatitis
(HAV, HBV, HCV, HDV), chronic alcoholism, HIV infec-
tion, yellow fever, dengue, leptospirosis, tuberculosis,
Hansen’s disease, visceral leishmaniasis, documented or
referred cancer and/or other chronic degenerative dis-
ease, sickle cell trait, and the use of hepatotoxic and
immunessupressive drugs. All participants or legal
responsible gave written informed consent before enter-
ing the study. This study was approved by the Ethical
Committee of the São Lucas University, Rondônia, Brazil,
for the human subject protocol.
Individuals were examined and interviewed and their
blood samples (20 mL) were collected for serological
experiments. In hospitalized participants, two venous
blood collections were performed: one at the hospital
admission and other seven days after malaria treatment
initiation. All malaria diagnoses were performed using
two methods. First, patients were screened by thick
smear examination using field microscopy and the para-
sitaemia (parasites/uL) was quantified in positive cases.
Further, nested PCR was performed in all whole blood
samples to confirm the diagnosis. Two individuals pre-
senting P. malariae infection and 16 people infected
with P. falciparum (uncomplicated forms) were identi-
fied and excluded from the study. Hence, all the volun-
teers selected were negative for P. falciparum and/or P.
malariae infection by both microscopic examination
and nested PCR.
A total of 219 individuals enrolled in the study. All
positive cases were followed for 30 days for the eva-
luation of malaria symptoms. Individuals who were
positive for P. vivax infection and remained without
fever (axillary temperature >37.8°C) and/or chills,
sweats, strong headaches, myalgia, nausea, vomiting,
jaundice, asthenia, and arthralgia for 30 days were
considered asymptomatic P. vivax-infected cases.
Cases showing positive parasitological tests in the pre-
sence of any symptom listed above were classified as
symptomatic infections. Patients presenting any sign
of acute severe organ dysfunction [25] were consid-
ered severe cases. Until today there are no clear cri-
teria defining what a severe vivax malaria case is.
Despite the absence of a consensus, this study used
the previously defined criteria for severe falciparum
infection [25]. Study individuals were then classified
within four groups: non-infected (n = 90), asympto-
matic (n = 60), mild (n = 50) and severe vivax infec-
tion (n = 19). The baseline characteristics of the
volunteers are listed in the Table 1.
Nested PCR for malaria diagnosis
The molecular diagnosis of malaria infection was per-
formed in all subjects using the nested PCR technique
described previously [26,27], with minimal alterations
[28]. To control for cross-contamination, one uninfected
blood sample was included for every twelve samples pro-
cessed. Fifteen percent of positive PCR samples were
retested to confirm the amplification of plasmodial DNA.
All tests were performed and confirmed at the Centro de
Pesquisas Gonçalo Moniz, Salvador, Bahia, Brazil.
Plasma cytokine levels detection
Plasma levels of IL-10, IFN-gamma, and TNF were mea-
sured using the Cytometric Bead Array - CBA (BD Bios-
ciences Pharmingen, USA) according to the
manufacturer’s protocol, with all samples running in a
single assay. The flow cytometric assay was performed
and analysed by a single operator, and standard curves
were derived from cytokine standards.
Andrade et al. Malaria Journal 2010, 9:13
http://www.malariajournal.com/content/9/1/13
Page 2 of 8Laboratory assessment of organ dysfunction
Plasma measurements of creatinin, aspartate amino-
transferase (AST), alanine amino-transaminase (ALT),
total and direct bilirubins, haemoglobin, and CRP were
made at the clinical laboratory of Faculdade São Lucas, at
the Pharmacy School (Federal University of Bahia, Brazil)
and at the Laboratório LPC (Salvador, Bahia. Brazil).
The Hepatic-Inflammatory Parasitic score
The hepatic-inflammatory parasitic (HIP) score was cre-
ated to standardize a reproducible evaluation of severity in
malaria cases. This score was developed by analysing data
from another study conducted in 2006 with a sample size
of 580 individuals from the Buritis Municipality, Rondônia
State, Brazil. This group was composed of non-infected
Table 1 Baseline characteristics of the participants.
Plasmodium vivax infection
Variables Non-infected N = 90 Asymptomatic N = 60 Mild N = 50 Severe N = 19
Male - no. (%) 39 (43.3) 30 (50.0) 22 (44.0) 10 (52.6)
Age - year *
Median 38.0 42.0 33.0 22.0
Interquartile interval 25.0 - 51.0 32.0 - 48.2 26.7 - 48.0 16.0 - 35.0
Previous malaria episodes *
Median 14.0 16.0 8.0 3.5
Interquartile interval 10.0 - 18.0 13.0 - 20.0 1.0 - 12 2.0 - 7.5
Years resident in the area *
Median 11.4 12.5 7.4 3.0
Interquartile interval 3.2 - 12.8 4.2 - 14.6 0.5 - 9.2 0.5 - 5.4
Parasitaemia (parasites/uL) *
Median 0 73 § 4,798 49,358
Interquartile interval 0 54.0 - 85.0 2,934 - 7,483 32,796 - 54,244
Haemoglobin (g/dL) *
Median 13.2 11.5 8.9 6.4
Interquartile interval 9.2 - 14.5 9.5 - 14.2 7.3 - 12.6 5.8 - 7.4
CRP (ng/mL)*
Median 5.65 6.6 6.5 15.3
Interquartile interval 3.7 - 9.47 4.12 - 9.35 4.9 - 8.7 11.9 - 20.65
Serum creatinine (mg/dL)*
Median 0.85 0.9 1.1 1.7
Interquartile interval 0.7 - 1.2 0.7 - 1.2 0.7 - 1.3 1.42 - 2.45
AST (U/L)*
Median 41.5 50.2 95.2 385.5
Interquartile interval 32.5 - 68.3 38.4 - 73.5 42.6 - 251.7 277.3 - 487.4
UNL 1.04 1.25 2.38 9.64
ALT (U/L)*
Median 42.35 40 58.3 238.4
Interquartile interval 37.28 - 53.58 23.25 - 65.78 43.6 - 87.5 105.5 - 364.6
UNL 1.06 1 1.46 4.96
Total bilirubin (mg/dL)*
Median 0.35 0.4 0.8 2.1
Interquartile interval 0.3 - 0.4 0.3 - 0.62 0.7 - 2.05 1.15 - 3.1
Direct bilirubin (mg/dL)
Median 0 0.11 0.3 1.1
Interquartile interval 0 - 0 0.01 - 0.4 0 - 1.63 0 - 2.2
Indirect bilirubin (mg/dL)
Median 0.3 0.28 0.5 1.1
Interquartile interval 0.28 - 0.37 0.2 - 0.3 0.45 - 0.72 0.6 - 1.3
CRP: C reactive protein; AST: aspartate aminotransferase; ALT: alanine amino-transferase; UNL: Upper normal levels. Data represent the number of times the
median of AST or ALT is higher than the standardized normal laboratory level (40 U/L). Ordinal variables were compared using the Kruskal Wallis test with Dunn’s
multiple comparisons. The prevalence of male gender was compared between the groups using chi-square test. §Six out of sixty individuals with asymptomatic
P. vivax infection were negative for malaria infection by light microscopy, but were positive for Plasmodium vivax infection by nested PCR. *Differences were
significant between groups (P < 0.05).
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presenting malaria-related symptoms (n = 195) or asymp-
tomatic infection (n = 202) composed this sample. In addi-
tion, this group was very similar to the one in 2007 with
regard to age, gender, time of residence in endemic area
and referred previous malaria episodes (data not shown).
Optimal threshold plasma values of AST, ALT, total bilir-
ubin, fibrinogen, CRP, and parasitaemia able to discrimi-
nate asymptomatic from symptomatic malaria infection
were calculated using the Receiver Operator Characteris-
tics (ROC) curves (Figure 1). For each variable measured,
the cut-off values presenting the higher sensitivity and spe-
cificity, as well as the highest likelihood ratio, were estab-
lished (Figure 1A-F). Further, one point was attributed to
each variable that presented higher than the established
cut-off value. Consequently, the minimum score was zero
and maximum was five, and it reflected both parasitaemia
and organ dysfunction aspects of symptomatic disease.
Once the score was established, it was tested by applying
to the sample constituted by the 219 participants
approached in this study (Figure 1G). Additionally, the
relationship between the HIP score and the IFN-gamma/
IL-10 was assessed, since this ratio has been used as indi-
cator of inflammatory activity in malaria [21,22,29].
Statistical analysis
Data were analyzed using the GraphPad Prism 5.0
(GraphPad Software Inc.). For the ordinal variables, dif-
ferences between groups were calculated using the non-
parametric Kruskal-Wallis test with Dunn’sm u l t i p l e
comparisons or trend analysis. The chi-square test was
used to compare differences in categorized variables.
The correlations were assessed using the Spearman test.
Non-linear curve fit was also plotted to illustrate the
general trend of the correlations. The statistical analyses
used are illustrated in each figure or table. Differences
presenting P ≤ 0.05 were considered statistically
significant.
Results and Discussion
Baseline characteristics and laboratory assessment of P.
vivax infection severity
The majority of the participants were male, with no gen-
der differences among groups (P = 0.78). As previously
described [4,28], individuals with asymptomatic P. vivax
infection were older, had experienced more previous
malaria episodes and presented lower parasitaemia than
had symptomatic cases (Table 1). Patients with severe P.
vivax infection were younger, having lived for a shorter
time in the endemic area, and had experienced fewer
previous malaria episodes than individuals with no
malaria infection and with mild or asymptomatic infec-
tion (Table 1). Moreover, patients with severe disease
Figure 1 The Hepatic-Inflammatory Parasitic score. In a primary
investigation, 580 individuals from Buritis, Rondonia, Brazil were
evaluated to standardize the Hepatic-Inflammatory Parasitic (HIP)
score. This sample included non-infected individuals (n = 183) and
those infected with Plasmodium presenting malaria-related
symptoms (n = 195) or asymptomatic infection (n = 202). The
threshold plasma values of (A) aspartate aminotransferase (AST), (B)
alanino amino-transaminase (ALT), (C) total bilirubin, (D) fibrinogen,
(E) C reactive protein (CRP) and (F) parasitaemia were established in
order to categorize the individuals according to the HIP score. Once
the HIP score was created, it was applied in another sample from
the same endemic area composed by 219 individuals: non-infected
(n = 90), asymptomatic (n = 60), mild (n = 50) and severe vivax
infection (n = 19). Area under the curve (AUC) was calculated,
together with the cut-off value, which presents the higher
likelihood ratio, and P values are plotted. The HIP score is described
in Methods.
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plicated infection (P < 0.0001). Haemoglobin levels were
also decreased in patients with severe disease (P = 0.02).
All patients with severe disease were admitted to the
municipal hospital presenting with fever, tachycardia
and tachypnea. Moreover, five out of nineteen indivi-
duals with severe infection developed jaundice and six
presented with splenomegaly. Six infected patients died
within 72 h of hospitalization, four presenting with
acute respiratory failure and two with anuric renal fail-
ure, despite the haemodynamic support and anti-para-
site therapy. These severe complications have been
commonly implicated as major death causes in severe
vivax infections [7,18]. The other thirteen individuals
with complicated disease received specific treatment
with intravenous quinine and achieved total clinical
recovery after 10-15 days. Clinical characteristics and
outcomes of the patients with severe malaria are sum-
marized in Table 2. All patients with mild disease recov-
ered totally and no drug resistance was identified within
individuals studied.
The further step was to assess whether the spectrum
of vivax malaria clinical presentation could be associated
with laboratory parameters of organ dysfunction. In a
primary analysis, strong linear trends were identified
regarding increasing plasma levels of CRP, serum creati-
nine, bilirubins and the graduation of disease severity
(Table 2; P < 0.0001 for all trends analyzed). The indivi-
duals presenting higher HIP scores also displayed ele-
vated IFN-gamma/IL-10 ratios (Figure 1G). These data
indicate that a high grade of general inflammation-
mediated systemic damage is occurring in some vivax
malaria cases, explaining the severity of their clinical
presentations.
Table 2 Characterization of the patients with severe vivax malaria.
Clinical presentation at
admission
P. vivax diagnosis
Patient No. Gender Age (y) Major
manifestation
Secondary
manifestation
Nested PCR Microscopy Outcome
1 M 15 Oliguria Hypotension,
splenomegaly
+ + Recovered
2 M 17 Respiratory
failure
Hypotension + + Recovered
3 F 9 Respiratory
failure
Hypotension + + Died
4 M 21 Severe anaemia Hypotension,
splenomegaly
+ + Recovered
5 M 22 Severe anaemia Hypotension + + Recovered
6 M 32 Anuric renal
failure
Hypotension,
splenomegaly
+ + Died
7 F 41 Respiratory
failure
Hypotension,
Jaundice
+ + Died
8 F 15 Severe anaemia Splenomegaly + + Recovered
9 M 15 Anuric renal
failure
Hypotension,
Jaundice
+ + Died
10 M 17 Severe anaemia Splenomegaly + + Recovered
11 F 13 Jaundice Splenomegaly + + Recovered
12 F 26 Jaundice Hypotension + + Recovered
13 M 32 Respiratory
failure
Hypotension + + Recovered
14 F 27 Seizure Jaundice + + Recovered
15 M 42 Oliguria Hypotension + + Recovered
16 F 38 Jaundice Hypotension + + Recovered
17 F 54 Respiratory
failure
Hypotension + + Died
18 M 24 Severe anaemia Hypotension + + Recovered
19 M 22 Respiratory
failure
Jaundice + + Died
Data regarding major and secondary manifestations were obtained from medical records and/or through the clinical exam at the hospital admission. Oliguria was
defined as estimated urinary output less than 400 mL/24 h and anuric renal failure as urinary output below 100 mL/24 h. Severe anaemia was defined as
haemoglobin levels below 7 g/dL and jaundice by clinical exam and bilirubin levels above 2.0. Hypotension was defined as the presence of related symptoms
with blood pressure below 100 × 40 mmHg. Respiratory failure was defined as tachypnea, shortness of breath, mental confusion clinical signs of hypoxaemia
(central and/or peripheral cyanosis).
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severity
Furthermore, a possible link between the differences in
clinical presentation and laboratory parameters of organ
damage and specific patterns of immune responses or
inflammatory mediators profile was evaluated. Plasma
TNF, which is related to P. vivax paroxysms [30], was
higher according to infection severity (Figure 2A). IFN-
gamma is also implicated in both resistance to malaria
[31] and disease immunopathology [32]. In the present
series, IFN-gamma levels were higher in patients with
increased severity (Figure 2B). Interestingly, the
increasing levels of all these inflammatory markers also
presented a linear trend with the gradual augmentation
of infection severity (P < 0.0001 for each parameter).
Conversely, plasma levels of IL-10, a cytokine that
down-regulates inflammation, were lower with increased
disease severity (P < 0.0001, for linear trend; Figure 2C).
Thus, IFN-gamma/IL-10 ratio values were higher in
patients with increased disease severity (P < 0.0001, for
linear trend; Figure 2D).
Kinetics of inflammatory responses during the treatment
of severe vivax infection
In thirteen patients, who clinically recovered out of nine-
teen with severe vivax infection, there was an important
reduction in the levels of all laboratory parameters of
organ damage screened, including plasma CRP (P =
0.002; Figure 3A), creatinine (P = 0.005; Figure 3B), ALT
(P = 0.001; Figure 3C) and total bilirubin (P = 0.016;
Figure 2 General trend of the Inflammatory profile in vivax
malaria. Plasma levels of (A) TNF, (B) IFN-gamma, (C) IL-10 and (D)
IFN-gamma/IL-10 ratios were estimated in non-infected individuals
and those presenting different manifestations of the vivax malaria
clinical spectrum. Study participants were stratified in groups as
follows: non-infected (NI; n = 90); asymptomatic infection (Asy; n =
60); mild infection (Mild; n = 50); and severe infection (Sev; n = 19).
One-Way ANOVA with trend analysis was performed to check the
statistical significance between the groups studied. P values are
plotted in each graph.
Figure 3 Kinetic of organ damage indicators during
antimalarial treatment in individuals with severe vivax disease.
Plasma levels of (A) CRP, (B) creatinine, (C), ALT and (D) total
bilirubin were estimated before treatment (at admission to the
Hospital) and after seven days of inhospital care in individuals with
severe vivax infection who achieved cure (n = 13). Wilcoxon
matched pairs test was performed to calculate the statistical
significance. P values are plotted in each graph.
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tion suggests that clinical recovery resulted from a reduc-
tion in systemic inflammatory aggression. Regarding the
immune markers of pro-inflammatory responses, an
important decrease in both IFN-gamma/IL-10 ratios (P =
0.0005; Figure 4A) and TNF levels (P = 0.001; Figure 4B)
was noticed during anti-malarial treatment.
Conclusions
These investigations suggest that different clinical pre-
sentations of vivax malaria infection are strongly asso-
ciated with a potent activation of pro-inflammatory
responses and cytokine imbalance. These results are of
utmost importance to improve current knowledge about
physiopathological concepts of this serious, widespread
disease.
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